Literature DB >> 17443220

JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.

S Schnittger, U Bacher, W Kern, T Haferlach, C Haferlach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17443220     DOI： 10.1038/sj.leu.2404707

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

Review 1.  Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

Authors:  Syed J Noor; Wei Tan; Gregory E Wilding; Laurie A Ford; Maurice Barcos; Sheila N J Sait; Annemarie W Block; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-08-19       Impact factor: 3.156

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

3.  Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Thomas Geer; Peter Müller; Johann Mittermüller; Petro Petrides; Rudolf Schlag; Reiner Sandner; Johannes Selbach; Hans Rainer Slawik; Hans Werner Tessen; Jürgen Wehmeyer; Wolfgang Kern; Torsten Haferlach
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

4.  Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Authors:  Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Olsnes Kittang; Randi Hovland; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2011-05-03

5.  Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia.

Authors:  Stephen E Langabeer; Karl Haslam; Maria Anne Smyth; John Quinn; Philip T Murphy
Journal:  Case Rep Hematol       Date:  2018-05-09

Review 6.  The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.

Authors:  Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Journal:  Ann Hematol       Date:  2007-10-16       Impact factor: 3.673

7.  JAK inhibitors suppress t(8;21) fusion protein-induced leukemia.

Authors:  M-C Lo; L F Peterson; M Yan; X Cong; J H Hickman; R C Dekelver; D Niewerth; D-E Zhang
Journal:  Leukemia       Date:  2013-07-01       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.